Abbott Laboratories (ABT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1149706,
    "name": "Abbott Laboratories",
    "stock_name": "Abbott Laboratories",
    "full_name": "Abbott Laboratories",
    "name_url": "stocks-analysis/abbott-laboratories",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "125.45",
    "chg": 0.33,
    "chgp": "0.26%",
    "dir": 1,
    "prev_price": "125.12",
    "mcapval": "258,487.47",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US0028241000",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "29.59 M",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/abbott-laboratories-1149706-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Abbott Laboratories overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-overvalued-or-undervalued-3728312",
        "imagepath": "",
        "date": "2025-11-25 11:13:52",
        "description": "As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price.\n\nIn comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods...."
      },
      {
        "title": "Is Abbott Laboratories overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-overvalued-or-undervalued-3723306",
        "imagepath": "",
        "date": "2025-11-23 11:09:25",
        "description": "As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price.\n\nIn comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance...."
      },
      {
        "title": "Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/abbott-laboratories-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-stock-price-decline-3619721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AbbottLaborator_technicaldot_3619721.png",
        "date": "2025-10-14 15:37:50",
        "description": "Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.38, reflecting a year of notable highs and lows. Technical indicators present mixed signals, while Abbott's year-to-date performance has outpaced the S&P 500, though longer-term returns remain less competitive."
      },
      {
        "title": "Is Abbott Laboratories technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-technically-bullish-or-bearish-3612750",
        "imagepath": "",
        "date": "2025-10-12 11:22:10",
        "description": "As of 10 October 2025, the technical trend for Abbott Laboratories has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish. The daily moving averages indicate a bullish stance. The Bollinger Bands show a sideways trend on the weekly chart and mildly bullish on the monthly chart. KST is bullish on both weekly and monthly time frames, but the OBV is mildly bearish weekly with no trend monthly. \n\nIn terms of performance, Abbott has outperformed the S&P 500 over the past month with a return of 2.48% compared to the S&P 500's 0.31%, and it has also shown strong year-to-date performance at 17.20% versus the S&P 500's 11.41%. However, over longer periods, Abbott's returns have lagged significantly behind the S&P 500. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators...."
      }
    ],
    "total": 12,
    "sid": "1149706",
    "stock_news_url": "https://www.marketsmojo.com/news/abbott-laboratories-1149706"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Abbott Laboratories overvalued or undervalued?

2025-11-25 11:13:52

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price. In comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods....

Is Abbott Laboratories overvalued or undervalued?

2025-11-23 11:09:25

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price. In comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance....

Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-14 15:37:50

Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.38, reflecting a year of notable highs and lows. Technical indicators present mixed signals, while Abbott's year-to-date performance has outpaced the S&P 500, though longer-term returns remain less competitive.

Is Abbott Laboratories technically bullish or bearish?

2025-10-12 11:22:10

As of 10 October 2025, the technical trend for Abbott Laboratories has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish. The daily moving averages indicate a bullish stance. The Bollinger Bands show a sideways trend on the weekly chart and mildly bullish on the monthly chart. KST is bullish on both weekly and monthly time frames, but the OBV is mildly bearish weekly with no trend monthly. In terms of performance, Abbott has outperformed the S&P 500 over the past month with a return of 2.48% compared to the S&P 500's 0.31%, and it has also shown strong year-to-date performance at 17.20% versus the S&P 500's 11.41%. However, over longer periods, Abbott's returns have lagged significantly behind the S&P 500. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators....

View All News